Swipe om te navigeren naar een ander artikel
The online version of this article (doi:10.1007/s11136-016-1426-z) contains supplementary material, which is available to authorized users.
Clinical trials in glioma patients with neurocognitive deficits face challenges due to lacking or unreliable patient self-reports on their health-related quality of life (HRQOL). Patient–proxy data could help solve this issue. We determined whether patient–proxy concordance levels were affected by patients’ neurocognitive functioning.
Patient and patient-by-proxy HRQOL ratings were assessed via SF-36 and EORTC QLQ-BN20, respectively, in 246 patients. Data on neurocognitive functioning were collected on a subgroup of 195 patients. Patient–proxy agreement was measured using the Bland–Altman limit of agreement, the mean difference, the concordance correlation coefficient (CCC), and the percentage difference (PD, ±0, 5, or 10 points). We defined patients to be cognitively impaired (n = 66) or cognitively intact (n = 129) based on their neurocognitive performance.
Patients rated their physical function and general health to be better than their proxies did, while at the same time, patients reported more visual disorders, communication deficits, itchy skin, and problems with bladder control. The cognitively impaired subgroup reported poorer physical functioning, more visual disorders, headaches, itchy skin, and issues with bladder control. In the cognitively intact group, no statistical significant differences were observed between patients and proxies. Not surprisingly, Bland–Altman plots revealed a high agreement between the patient and patient-by-proxy rating in all HRQOL domains ranging from 95 to 99 %. The CCC was fairly high in all HRQOL domains (0.37–0.80), and the percentage of perfect agreement (PD ± 0) ranged from 8.5 to 76.8 %. In the cognitively impaired patients, the mean difference between patients and proxies was overall larger, and accordingly, agreement based on Bland–Altman plots was lower.
The level of agreement between patient and patient-by-proxy ratings of low-grade glioma patients’ HRQOL is generally high. However, patient–proxy agreement is lower in patients with neurocognitive deficits than in patients without neurocognitive deficits.
Supplementary material 1 (DOCX 80 kb)11136_2016_1426_MOESM1_ESM.docx
Taphoorn, M. J., van den Bent, M. J., Mauer, M. E., Coens, C., Delattre, J. Y., Brandes, A. A., et al. (2007). Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: Results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. Journal of Clinical Oncology, 25(36), 5723–5730. CrossRefPubMed
Brown, P. D., Decker, P. A., Rummans, T. A., Clark, M. M., Frost, M. H., Ballman, K. V., et al. (2008). A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: Comparison of patient and caregiver ratings of quality of life. American Journal of Clinical Oncology, 31(2), 163–168. CrossRefPubMed
Bland, J. M., & Altman, D. G. (1986). Statistical methods for assessing agreement between two methods of clinical measurement. The Lancet, 1(8476), 307–310. CrossRef
Klein, M., Heimans, J. J., Aaronson, N. K., van der Ploeg, H. M., Grit, J., Muller, M., et al. (2002). Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: A comparative study. The Lancet, 360(9343), 1361–1368. CrossRef
Stewart, A. L., & Ware, J. E. (Eds.). (1992). Measuring functioning and well-being: The medical outcomes study approach. Durham, NC: Duke University Press.
Osoba, D., Aaronson, N. K., Muller, M., Sneeuw, K., Hsu, M. A., Yung, W. K., et al. (1996). The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Quality of Life Research, 5(1), 139–150. CrossRefPubMed
Aaronson, N. K., Muller, M., Cohen, P. D., Essink-Bot, M. L., Fekkes, M., Sanderman, R., et al. (1998). Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. Journal of Clinical Epidemiology, 51(11), 1055–1068. CrossRefPubMed
van Dam, F. S., Schagen, S. B., Muller, M. J., Boogerd, W., vd Wall, E., Droogleever Fortuyn, M. E., et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90(3), 210–218. CrossRefPubMed
Karnofsky, D. A., Abelmann, W. H., & Craver, L. F. (1948). The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer, 1, 634–656. CrossRef
Karnofsky, D. A., & Burchenal, J. H. (1949). The clinical evaluation of chemotherapeutic agents in cancer. In C. M. Macleod (Ed.), Evaluation of chemotherapeutic agents (pp. 199–205). New York: Columbia University Press.
Ware, J. E., Kosinski, M., & Dewey, J. E. (2000). How to score version 2 of the SF-36 health survey. Lincoln, RI: Quality Metric Inc.
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., et al. (2001). EORTC QLQ-C30 scoring manual (3rd ed.). Brussels: EORTC.
Altman, D. G., & Bland, J. M. (1983). Measurement in medicine: The analysis of method comparison studies. The Statistician, 32, 307–317. CrossRef
Bland, J. M., & Altman, D. G. (1995). Comparing methods of measurement: Why plotting difference against standard method is misleading. The Lancet, 346(8982), 1085–1087. CrossRef
Burns, N., & Grove, S. K. (1997). The practice of nursing research conduct, critique, and utilization (3rd ed.). Philadelphia: W.B. Saunders & Co.
Brown, P. D., Buckner, J. C., O’Fallon, J. R., Iturria, N. L., Brown, C. A., O’Neill, B. P., et al. (2003). Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. Journal of Clinical Oncology, 21(13), 2519–2524. CrossRefPubMed
- Impact of neurocognitive deficits on patient–proxy agreement regarding health-related quality of life in low-grade glioma patients
Divine E. Ediebah
Jaap C. Reijneveld
Martin J. B. Taphoorn
Neil K. Aaronson
Jan J. Heimans
on behalf of the EORTC Quality of Life Department and Patient Reported Outcome and Behavioral Evidence (PROBE)
- Springer International Publishing